Skip to content

Study · Case report or series · n = 1 · 2024

1 result

An Overlooked Medication-Induced Celiac Flare Complicating Treatment of Osteoporosis.

Phan V, Aurora J Jr, Gondi S, Ceglia L

AACE clinical case reports11 Jan 2024Cited by 1 (Europe PMC)

PMID38523850 (opens in a new tab)PMCIDPMC10958639 (opens in a new tab)DOI10.1016/j.aace.2024.01.001 (opens in a new tab)PepBankPUB-38523850
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    After gluten-related abnormalities resolved, the patient resumed abaloparatide without biochemical abnormalities.

    In plain wordsThe patient resumed abaloparatide without abnormal biochemical results after the gluten-related problem resolved.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBiochemical abnormalities on rechallenge
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum ALP and PTH levels normalized, and abaloparatide was resumed without biochemical abnormalities.
    2 context sentences
    Summary · context
    A patient with long-standing celiac disease on a strict gluten-free diet and long-term glucocorticoid therapy status post kidney transplant for Sjögren syndrome-induced interstitial nephritis presented for management of osteoporosis.
    Summary · context
    Given normal serum total alkaline phosphatase (ALP) and parathyroid hormone (PTH), she began treatment of osteoporosis with abaloparatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.